Skip to main content
Premium Trial:

Request an Annual Quote

Citadel Ups Stake in Affymetrix

NEW YORK (GenomeWeb News) – One of the world’s largest hedge funds, Citadel Investment Group, has raised its stake in Affymetrix to 5.5 percent of the microarray firm’s outstanding stock.
 
Citadel reported in a US Securities and Exchange Commission earlier this week that it now owns 3,861,403 shares of Affy. That stake is up significantly from the roughly 827,000 shares Citadel held in the firm as of the end of 2007.
 
Affy’s shares were up .1 percent at $19.44 in early Thursday trade on the Nasdaq, off its 52-week high of $31.95, reached in April 2007.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.